Ivana Šestak - Concepedia

Author

Ivana Šestak

Also Known As

Curigliano, G., I Sestak, I. Sestak, Ivana Sestak, Ivana Šestak, Ivana Šumanovac Šestak, Sestak, Ivana, Šumanovac Šestak, Ivana

195

Publications

11.3K

Citations

H-Index

Concepts

All Affiliations

Queen Mary University of London Royal Marsden Hospital Breast Cancer Now Cancer Research UK Institute of Cancer Research

IŠ

About

Ivana Šestak is an author at Queen Mary University of London specializing in medicine, breast cancer, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	12	13	3.4K
2	Public Health	3	3	71
3	Endocrinology	2	2	56
4	Health Sciences	1	1	13
5	Biostatistics	1	1	18

Ivana Šestak

Publications

10.2K

Citations

H-Index

Page 1

	Year	Citations
Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial Jack Cuzick, Ivana Šestak, Michael Baum, The Lancet Oncology Breast OncologyOncologyAtac TrialPharmacologyAdjuvant Treatment	2010	1.7K
Comparison of PAM50 Risk of Recurrence Score With Onco<i>type</i> DX and IHC4 for Predicting Risk of Distant Recurrence After Endocrine Therapy Mitch Dowsett, Ivana Šestak, Elena López‐Knowles, Journal of Clinical Oncology	2013	632
Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial Jack Cuzick, Ivana Šestak, John Forbes, The Lancet Breast OncologyMedicineCancer ManagementPharmacologyClinical Trials	2013	578
Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial Jack Cuzick, Ivana Šestak, Sarah E. Pinder, The Lancet Oncology	2010	564
Development and verification of the PAM50-based Prosigna breast cancer gene signature assay Brett Wallden, James J. Storhoff, Torsten O. Nielsen, BMC Medical Genomics	2015	543
Long-Term Results of Tamoxifen Prophylaxis for Breast Cancer--96-Month Follow-up of the Randomized IBIS-I Trial Jack Cuzick, JF Forbes, Ivana Šestak, JNCI Journal of the National Cancer Institute	2007	533
Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial Jack Cuzick, Ivana Šestak, Simon Cawthorn, The Lancet Oncology	2014	451
Lancet Oncol 10 Jack Cuzick, Ivana Šestak, Sarah E. Pinder, Clinical TranslationClinical EndpointPharmacotherapyMedicineLancet Oncol 10	2013	431
Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population Dennis C. Sgroi, Ivana Šestak, Jack Cuzick, The Lancet Oncology Transatac Study PopulationBreast OncologyMedicineCancer RecurrenceBreast-cancer Index	2013	388
Comparison of the Performance of 6 Prognostic Signatures for Estrogen Receptor–Positive Breast Cancer Ivana Šestak, Richard Buus, Jack Cuzick, JAMA Oncology	2018	322

Page 1